Related Experiment Videos
The transcriptome's drugable frequenters
1N.V. Organon, Department of Target Discovery, Room RE2106, PO Box 20, 5340 BH Oss, The Netherlands. koen.dechering@organon.com
Drug Discovery Today
|June 23, 2005
Summary
Microarray studies for drug discovery face challenges. While drug targets are underrepresented in normal tissues, they appear in differential gene expression, offering a path for identifying new drug targets.
Area of Science:
- Genomics
- Drug Discovery
- Transcriptomics
Background:
- Microarray studies are crucial for early drug discovery.
- The genomics revolution promised rapid identification of novel drug targets.
- Key questions regarding gene representation in transcriptomes were overlooked.
Purpose of the Study:
- To explore the representation of drug targets and signaling pathway components in the transcriptome.
- To assess the suitability of microarray technology for drug target identification.
- To investigate gene expression patterns in non-pathological and differential transcriptomes.
Main Methods:
- Review of existing literature on microarray studies and transcriptomics.
- Analysis of gene expression data focusing on drugable gene families.
- Comparison of gene representation in normal versus differential transcriptomes.
Main Results:
- Members of drugable gene families are underrepresented in non-pathological human tissue transcriptomes.
- These drugable genes are represented at expected frequencies in the differential transcriptome.
- Microarray technology may have limitations in detecting poorly expressed genes.
Conclusions:
- Genome-wide differential gene expression analysis provides a comprehensive view of cellular pathways.
- This approach is valuable for identifying potential drug targets.
- Understanding gene representation is critical for effective drug discovery using transcriptomic data.